Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma.
Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma.
复制标题
DOI：
10.3389/fonc.2022.967159
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Chen, Qianxue
中科院分区：
文献类型：
--
作者：
Ye, Zhang;Zhang, Shenqi;Cai, Jiayang;Ye, Liguo;Gao, Lun;Wang, Yixuan;Tong, Shiao;Sun, Qian;Wu, Yu;Xiong, Xiaoxing;Chen, Qianxue
WHO 2/3胶质瘤是一种常见的颅内肿瘤，严重影响患者的生活质量和生存时间。既往研究表明三羧酸（TCA）循环与胶质瘤的发生、发展密切相关，而近期研究表明铜凋亡这种新型程序性死亡途径与TCA循环的抑制密切相关。在我们的研究中，发现十个铜凋亡相关基因 (CRG) 中有八个在正常组织和 WHO 2/3 胶质瘤组织之间存在差异表达。通过LASSO算法构建了铜凋亡相关风险特征（CARS），可以有效预测WHO 2/3胶质瘤患者的预后，且与临床病理特征密切相关。我们通过Xcell、ssGSEA、TIMER数据库和免疫检查点分子分析了风险评分与免疫细胞浸润之间的关系。此外，还研究了风险评分与化疗药物敏感性之间的关系。从 CARS 中鉴定出的与预后相关的独立危险因素 FDX1 和 CDKN2A 被认为是 WHO 2/3 胶质瘤的潜在预后生物标志物。基于铜凋亡的临床预后模型有望为临床WHO 2/3胶质瘤患者的诊治提供有效参考。
WHO 2/3 glioma is a common intracranial tumor that seriously affects the quality of life and survival time of patients. Previous studies have shown that the tricarboxylic acid (TCA) cycle is closely related to the occurrence and development of glioma, while recent studies have shown that cuproptosis, a novel programmed death pathway, is closely related to the inhibition of the TCA cycle. In our study, eight of ten cuproptosis-related genes (CRGs) were found to be differentially expressed between normal and WHO 2/3 glioma tissues. Through the LASSO algorithm, the cuproptosis-associated risk signatures (CARSs) were constructed, which can effectively predict the prognosis of WHO 2/3 glioma patients and are closely related to clinicopathological features. We analyzed the relationship between risk score and immune cell infiltration through Xcell, ssGSEA, TIMER database, and immune checkpoint molecules. In addition, the relationship between risk score and chemotherapeutic drug sensitivity was also investigated. The prognosis-related independent risk factors FDX1 and CDKN2A identified from CARSs are considered potential prognostic biomarkers for WHO 2/3 glioma. The clinical prognosis model based on cuproptosis is expected to provide an effective reference for the diagnosis and treatment of clinical WHO 2/3 glioma patients.
登录
查看更多内容
影响因子：
14.9
作者：
Ritchie ME;Phipson B;Wu D;Hu Y;Law CW;Shi W;Smyth GK
通讯作者：
Smyth GK
DOI：
10.1056/nejmoa1407279
发表时间：
2015-06-25
期刊：
The New England journal of medicine
影响因子：
--
作者：
Eckel-Passow JE;Lachance DH;Molinaro AM;Walsh KM;Decker PA;Sicotte H;Pekmezci M;Rice T;Kosel ML;Smirnov IV;Sarkar G;Caron AA;Kollmeyer TM;Praska CE;Chada AR;Halder C;Hansen HM;McCoy LS;Bracci PM;Marshall R;Zheng S;Reis GF;Pico AR;O'Neill BP;Buckner JC;Giannini C;Huse JT;Perry A;Tihan T;Berger MS;Chang SM;Prados MD;Wiemels J;Wiencke JK;Wrensch MR;Jenkins RB
通讯作者：
Jenkins RB
DOI：
10.1093/annonc/mdx230
发表时间：
2017-08-01
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Jakola AS;Skjulsvik AJ;Myrmel KS;Sjåvik K;Unsgård G;Torp SH;Aaberg K;Berg T;Dai HY;Johnsen K;Kloster R;Solheim O
通讯作者：
Solheim O
影响因子：
22.7
作者：
Corsello, Steven M.;Nagari, Rohith T.;Golub, Todd R.
通讯作者：
Golub, Todd R.
影响因子：
6
作者：
Merker, K;Hapke, D;Grune, T
通讯作者：
Grune, T